Molecular characterization plays a growing role in diagnosis and precision therapy, exemplified by the identification of ETV6–NTRK3 fusions in secretory carcinoma and MYB rearrangements in adenoid cystic carcinoma. Here, ETV6 is linked to adenoid cystic carcinoma.